MannKind CEO Michael Castagna (file photo) Westlake Village-based MannKind Corporation is on the offensive and the company made it apparent with its latest purchase. Announced Aug. 25, MannKind is acquiring scPharmaceuticals, a Massachusetts-based biotech company that specializes in cardiorenal medicine, for $360 million, or $5.35 per share. The move helps diversify MannKind’s pipeline, adding an…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
